Hims & Hers (HIMS) Sees Analyst Optimism Following Novo Resolution

Hims & Hers Health, Inc. (NYSE:HIMS) is one of the 11 Best Day Trading Stocks to Buy Now. Investment bank Barclays discussed Hims & Hers Health, Inc. (NYSE:HIMS)’s shares on March 11th. It raised the share price target to $29 from $25 and kept an Overweight rating on the stock. Barclays commented that the fact that Hims & Hers Health, Inc. (NYSE:HIMS)’s shares had performed well after its agreement with Novo Nordisk indicated that the firm’s legal woes were behind it. Barclays added that the market appear ...